Clinical Research Papers:
Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study
Metrics: PDF 974 views | HTML 1133 views | ?
Xi Jin1,*, Yi-Zhou Jiang1,*, Sheng Chen1,*, Ke-Da Yu1, Zhi-Ming Shao1, Gen-Hong Di1
1Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
*These authors have contributed equally to this work
Gen-Hong Di, e-mail: firstname.lastname@example.org
Yi-Zhou Jiang, e-mail: email@example.com
Keywords: breast cancer, neoadjuvant chemotherapy, receptor conversion, prognosis
Received: January 12, 2015 Accepted: February 05, 2015 Published: March 16, 2015
The hormone receptor (HR) status and human epidermal growth hormone receptor 2 (HER2) status of patients with breast cancer may change following neoadjuvant chemotherapy (NCT). This prospective observational study aimed to evaluate the prognostic impact of receptor conversion in breast cancer patients treated with NCT.Of the 423 consecutive patients who had residual disease in the breast after NCT, 55 (13.0%) changed from HR (+) to HR (−), 23 (5.4%) changed from HR (−) to HR (+), 27 (6.4%) changed from HER2 (+) to HER2 (−), and 13 (3.1%) changed from HER2 (−) to HER2 (+). A total of 54 (12.8%) changed to the triple-negative (TN) tumor phenotype. The loss of HR positivity was an independent prognostic factor for worse disease-free survival (DFS) and worse overall survival (OS) in multivariate survival analysis. Furthermore, the switch to the TN phenotype after NCT was another independent prognostic factor for worse survival for both DFS and OS. In conclusion, patients with breast cancer may experience changes in HR status, HER2 status and tumor phenotype after NCT. The loss of HR positivity and the switch to the TN phenotype after NCT were associated with a worse patient outcome.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.